Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Prophylactic Phasix™ Mesh for Incisional Hernia Prevention in IBD Surgery: A Prospective Multicenter Study (ProPhIS)

17. november 2026 oppdatert av: Matteo Rottoli, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Assessing the Incidence of Incisional Hernia Rates in Inflammatory Bowel Disease Patients Undergoing Open or Minimally Invasive Abdominal Surgery With Use of Prophylactic Phasix™ Mesh Reinforcement: A Multicenter, Single-Arm, Two Strata Prospective Study.

The goal of this clinical trial is to evaluate the incidence of incisional hernia, detected by ultrasound imaging, two years after surgery in patients with Inflammatory Bowel Disease (IBD) undergoing either open or minimally invasive abdominal surgery with the use of prophylactic Phasix™ Mesh reinforcement. The study focuses on consecutive adult patients aged 18 years or older with a confirmed histological diagnosis of Crohn's disease or Ulcerative Colitis who are scheduled for elective abdominal surgery, specifically minimally invasive surgery requiring a periumbilical incision for specimen extraction or open abdominal surgery via a midline incision for patients undergoing their second or subsequent abdominal operation for IBD. The main questions it aims to answer are: what is the rate of 24-month incisional hernia as diagnosed by ultrasound imaging in the prospective study population, and how do secondary outcomes such as postoperative pain, quality of life, surgical site occurrences, and 90-day complication rates compare across these surgical strata? If there is a comparison group: Researchers will compare participants who received open surgery to those who received minimally invasive surgery to see if there are significant differences in the 24-month incisional hernia rates, complication profiles, and recovery metrics. Participants will undergo their planned abdominal surgery according to standard institutional care pathways, during which the study device-the Phasix™ Mesh-will be positioned to reinforce either the periumbilical extraction site in minimally invasive procedures or the midline incision in open surgeries using a standardized onlay technique. Following surgery, participants will be asked to complete a series of main tasks and evaluations, which include providing daily self-reported pain ratings on a Visual Analog Scale during hospitalization, attending scheduled follow-up visits at 30 days, 6 months, 12 months, and 24 months post-surgery, undergoing clinical evaluations and wound inspections with standardized photographic documentation at each visit, completing validated questionnaires including the Short-Form Health Survey-36, Ventral Hernia Pain Questionnaire, and Carolinas Comfort Scale at specified postoperative time points, and undergoing delegated ultrasound imaging of the entire length of the incision in both supine resting and dynamic states during the 12-month and 24-month follow-up visits to detect any occult or overt fascial defects or herniation.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

150

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adult patients aged ≥ 18 years at the time of screening.

  • Confirmed (histologically proven) diagnosis of Crohn's disease or Ulcerative Colitis.

  • Scheduled to undergo abdominal surgery, specifically:

    • Minimally invasive surgery (laparoscopic or robotic) requiring a periumbilicaln incision for specimen extraction.
    • Open abdominal surgery (laparotomy) via a midline incision, for patients undergoing their second or subsequent abdominal operation for IBD.
  • Willingness and ability to provide informed consent.

  • Willingness and ability to comply with follow-up requirements, including ultrasound examinations.

Exclusion Criteria:

  • Emergency surgery (e.g., for perforation with gross contamination, hemodynamic instability requiring immediate life-saving surgery without time for prophylactic mesh consideration).
  • Presence of an existing incisional hernia at the planned incision site.
  • Known allergy or hypersensitivity to any components of Phasix™ Mesh. In particular, known allergy to tetracycline hydrochloride or kanamycin sulfate.
  • Current gross abdominal sepsis or infection that, in the surgeon's judgment, would contraindicate mesh placement.
  • Life expectancy less than two years.
  • Pregnant or breastfeeding women.
  • Participation in another interventional trial that might confound the study results.
  • Previous mesh placement at the index incision site (for open surgery patients)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: MIS with Phasix Mesh Reinforcement

Patients with Inflammatory Bowel Disease undergoing elective minimally invasive (laparoscopic or robotic) abdominal surgery who receive prophylactic Phasix Mesh reinforcement of the periumbilical specimen extraction site using a standardized technique.

A fully resorbable monofilament scaffold (Phasix Mesh) placed during elective abdominal surgery to reinforce either the periumbilical specimen extraction site in minimally invasive surgery or the midline incision in open surgery, using a standardized onlay technique.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
the rate of 24-month incisional hernia
Tidsramme: baseline

diagnosed by ultrasound imaging

baseline

Sekundære resultatmål

Resultatmål
Tidsramme
rate of 12-month incisional hernia
Tidsramme: baseline
baseline
median value of the participants-reported pain
Tidsramme: study visits after surgey
study visits after surgey
The median value of the Ventral Hernia Pain Questionnaire (VHPQ)
Tidsramme: after surgery
after surgery
The median value of the Short-Form Health Survey-36 (SF-36)
Tidsramme: after surgery
after surgery
The median value of the Carolinas Comfort Scale (CCS)
Tidsramme: after surgery
after surgery
The median difference in the 24-month VAS scores
Tidsramme: 24 month after surgery
24 month after surgery
The rate of 90-day postoperative complications classified according to the Clavien-Dindo scale
Tidsramme: 90 after surgery
90 after surgery
The rate of 90-day reoperations
Tidsramme: 90 after surgery
90 after surgery
The rate of 24-month incisional hernia between the participants who received open surgery and those who received MIS.
Tidsramme: 24 months after surgery
24 months after surgery
The median difference in the 24-month VHPQ scores
Tidsramme: 24 months after surgery
24 months after surgery
The median difference in the 24-month SF-36 scores
Tidsramme: 24 months after surgery
24 months after surgery
The median difference in the 24-month CCS scores
Tidsramme: 24 months after surgery
24 months after surgery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

31. desember 2026

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

31. desember 2029

Datoer for studieregistrering

Først innsendt

10. november 2026

Først innsendt som oppfylte QC-kriteriene

17. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ProPhIS
  • CyberGrant 103751599 (Annet stipend/finansieringsnummer: Becton Dickinson Holdings Pte Ltd)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .